Cargando…
Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus
Type I interferons are implicated in the pathogenesis of systemic lupus erythematosus (SLE). Type I interferon-inducible mRNAs are widely and concordantly overexpressed in the periphery and involved tissues of a subset of SLE patients, and provide utility as pharmacodynamic biomarkers to aid dose se...
Autores principales: | Yao, Yihong, Higgs, Brandon W, Richman, Laura, White, Barbara, Jallal, Bahija |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2991779/ https://www.ncbi.nlm.nih.gov/pubmed/20392292 http://dx.doi.org/10.1186/ar2887 |
Ejemplares similares
-
Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus
por: Yao, Yihong, et al.
Publicado: (2009) -
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients
por: Higgs, Brandon W, et al.
Publicado: (2014) -
Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
por: Narwal, Rajesh, et al.
Publicado: (2013) -
Efficacy of sifalimumab for treatment of skin injury caused by systemic lupus erythematosus
por: Huo, Ai-xin, et al.
Publicado: (2019) -
Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)